A U.S. humanitarian waiver will allow people in several countries to continue accessing life-saving HIV treatments, the UNAIDS said on Wednesday, after President Donald Trump's freeze on foreign aid threatened such supplies.

The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria, and tuberculosis in countries supported by USAID around the globe.

In a last-minute move, the Trump administration issues an emergency waiver to ensure millions of people in 55 countries continue receiving life-saving HIV treatment.

A move by the Trump administration to freeze funding for PEPFAR, the widely heralded international HIV/AIDS program, is putting countless lives at immediate risk, experts say.

The Trump administration's aid freeze affects HIV treatment access. Find out how organizations are coping with the directive.

Almost 136,000 babies are expected to be born with HIV in the next three months, mostly in Africa, because of the Trump administration’s “stop work order” on foreign assistance, according to a top research foundation.

WHO said that over the past year, PEPFAR and partners – including WHO – “have been working on sustainability plans with countries for greater country ownership and reduced donor support up to and beyond 2030.

If it hadn’t come through, we still had sufficient stocks in the short term and hoped that Government would plan to bridge the gap in medium and long term

But on Tuesday, after public outcry, the Trump administration walked back its ban on distributing HIV medication to patients who need it. Secretary of State Marco Rubio announced that the State Department would offer a waiver for lifesaving medication. It’s not clear if this applies to preventative medication offered by PEPFAR, like PrEP.

The President’s Emergency Plan for AIDS Relief (PEPFAR), a federal program that provides HIV medications, is one of the programs on pause during a 90-day review ordered by the Secretary of State.

Almost 1 in 10 patients receiving HIV care may have binge eating disorder (BED), a significantly higher rate than the 0.3% reported in the general population, according to a cross-sectional study. Individuals with possible BED were six times more likely than others to have clinical obesity and twice as likely to be overweight.